Fig. 3: Transcriptomic analysis reveals a substantial disparity between CDX_IBP_01 and primary tumour gene expression profiles.
From: Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer
a Venn diagram portraying genes downregulated and upregulated in CTCs-derived xenograft (CDX_IBP_01) relative to the primary tumour (BCa1) (Fold Change >2) determined by RNA-seq. b Heatmap representing z-score for top 5000 genes deregulated in CDX_IBP_01 vs. BCa1. c Volcano plot depicting the distribution of differentially expressed genes with the 10 most downregulated and 10 most upregulated genes within CDX_IBP_01 relative to BCa1. d Dot plot representing Gene Ontology Biological Processes enriched (left) or lost (right) within CDX_IBP_01 relative to BCa1. The dot size represents the number of genes of a particular biological process; the colour intensity represents the fold enrichment (CDX_IBP_01 vs. BCa1), and the x-axis determines the −log10 false discovery rate. e List of the 10 most positively- and negatively enriched gene sets from the Hallmarks database. f GSEA plots depicting the most deregulated Hallmarks biological processes between CDX_IBP_01 and BCa1 related to cellular signalling. g GSEA plots depicting the most deregulated Hallmarks biological processes between CDX_IBP_01 and BCa1 related to metabolism.
